Reference  is made  to the  stock exchange  announcement by  Hofseth BioCare ASA
("HBC"  or the "Company")  on 27 October 2025 regarding  completion of a private
placement (the "Private Placement") of new shares in the Company.

The  following  shareholders  of  the  Company  have,  on  27 October 2025, been
allocated  new shares in the Private Placement which implies that their holdings
have surpassed a notifiable threshold:

  * Guy Urquhart have subscribed for 55,444,444 new shares in the Private
    Placement. Following this, Guy Urquhart holds 55,444,444 shares in the
    Company, corresponding to 12.21% of the shares in the Company and 12.21% of
    the votes at the Company's general meetings.

The following shareholders have had their holdings diluted as a consequence of
the Private Placement and thereby surpassed a notifiable threshold:

  * Following completion of tranche 1 in the Private Placement, funds managed by
    Bonafide Wealth Management holds 66,023,125 shares in the Company,
    corresponding to 14.54% of the ordinary shares in the Company and 14.54% of
    the votes at the Company's general meetings.
  * Following completion of tranche 1 in the Private Placement, Aqua-Spark holds
    22,433,338 shares in the Company, corresponding to 4.94% of the ordinary
    shares in the Company and 4.94% of the votes at the Company's general
    meetings.
  * Following completion of tranche 1 in the Private Placement, Yokorei Co. Ltd.
    holds 40 951 333 shares in the Company, corresponding to 9.02% of the
    ordinary shares in the Company and 9.02% of the votes at the Company's
    general meetings.

This  disclosure is  made pursuant  to section  4-2 of the  Norwegian Securities
Trading  Act and  is subject  to the  disclosure requirement pursuant to section
5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no (mailto:joo@hofsethbiocare.no)